Sun Pharmaceutical Industries Limited ((IN:SUNPHARMA)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sun Pharmaceutical Industries Limited is conducting a study titled A Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescent Patients With Severe Alopecia Areata With an Open-label Extension Period. The study aims to assess the safety and effectiveness of deuruxolitinib in adolescents with significant hair loss due to alopecia areata, a condition causing hair loss.
The intervention being tested is deuruxolitinib, an experimental drug administered orally at a dose of 8 mg twice daily. The study includes a placebo group for comparison. The primary goal is to evaluate the treatment’s effectiveness in reducing hair loss.
The study design is interventional, with participants randomly assigned to either the treatment or placebo group. It follows a parallel assignment model with quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are blinded to the treatment during the initial phase. An open-label extension follows the initial treatment period.
The study began on July 29, 2025, with the most recent update on August 13, 2025. These dates are crucial as they mark the study’s progress and ongoing recruitment status.
This study update could influence Sun Pharmaceutical’s stock performance, as successful results may boost investor confidence and market position, especially in the competitive pharmaceutical industry focusing on dermatological conditions.
The study is currently ongoing, and further details are available on the ClinicalTrials portal.